Influx HealthtechNSE:INFLUX -5.30%21 Quick Ratio is 2.89 as of Mar. 2026, which is 163% above its 10-year median of 1.10. GuruFocus rates NSE:INFLUX with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 997 Drug Manufacturers companies, Influx Healthtech ranks better than 75.33% on this metric.
Influx Healthtech has a quick ratio of 2.89. It generally indicates good short-term financial strength.
The historical rank and industry rank for Influx Healthtech's Quick Ratio or its related term are showing as below:
NSE:INFLUX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.97 Med: 1.1 Max: 2.89
Current: 2.89
During the past 5 years, Influx Healthtech's highest Quick Ratio was 2.89. The lowest was 0.97. And the median was 1.10.
NSE:INFLUX's Quick Ratio is ranked better than 75.33% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs NSE:INFLUX: 2.89
Influx Healthtech (NSE:INFLUX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Influx Healthtech Quick Ratio Related Terms
Influx Healthtech Quick Ratio Historical Data
* Premium members only.
The historical data trend for Influx Healthtech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Influx Healthtech Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Influx Healthtech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Influx Healthtech's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Influx Healthtech (NSE:INFLUX) has a Quick Ratio of 2.89 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Influx Healthtech and its competitors. This is 163% above median its historical median of 1.10. Over the past decade, Influx Healthtech's Quick Ratio has ranged from 0.97 to 2.89. According to the industry distribution chart, Influx Healthtech ranks #246 out of 997 companies in the Drug Manufacturers industry, placing it in the top 24.7%.
Is Influx Healthtech's Quick Ratio too high?
Influx Healthtech's current Quick Ratio of 2.89 is 163% above median its 10-year median of 1.10. Over the past 10 years, this metric has ranged from a low of 0.97 to a high of 2.89. The Drug Manufacturers industry median Quick Ratio is 1.45. Influx Healthtech's value of 2.89 is 99.3% above this industry median. Based on the distribution chart, Influx Healthtech ranks #246 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Influx Healthtech has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Influx Healthtech ranks #246 out of 997 companies for Quick Ratio. This places Influx Healthtech in the top 25% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Influx Healthtech's value of 2.89 is 99.3% above this benchmark. Historically, Influx Healthtech's own Quick Ratio has ranged from 0.97 to 2.89 over the past decade. While the company's 10-year median is 1.10 vs. the industry median of 1.45, Influx Healthtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current Quick Ratio of 2.89 is 99.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current Quick Ratio is 2.89, which is 163% above median its own 10-year median of 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current Quick Ratio of 2.89. The current Quick Ratio is 2.89, which is 163% above median its 10-year median of 1.10 and 99.3% above the Drug Manufacturers industry median of 1.45. Influx Healthtech's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current Quick Ratio is 2.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
21GF Score
Get the complete analysis for NSE:INFLUX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFLUX has been successfully added to your 